Sensitivity of canine and human cancer cells to inhibitors targeting class I PI3K/Akt/mTOR pathway. Cells were treated with a range of doses of the pan-class I PI3K inhibitor ZSTK474 for 3 days (A), Akt inhibitor KP372-1 for 2 days (B), or mTOR inhibitor Rapamycin for 3 days (C). After drug treatment, the number of viable cells was determined by using CellTiter-Glo® Luminescent Cell Viability Assay. Results were expressed as mean (±SD) counts of quadruplicate wells. The values of the viability rates of the drug-treated cells were compared with the vehicle (DMSO)-treated cells on the same culture plates.